High-yield points
- SDR:
- Evidence: RCT-proven to reduce spasticity, with a small functional gain (GMFM +4) .
- Best candidate: the young ambulatory child with pure spastic diplegia .
- Later course: spine and orthopedic problems mostly follow CP's natural history .
- ITB:
- Best candidate: severe generalized spasticity or dystonia, GMFCS IV–V; it beat placebo in dyskinetic CP .
- Complications: expect them in most patients, mainly catheter problems and pseudomeningocele .
- ITB test dose: a 50-μg bolus (25 μg in small children), but it is not always necessary .
- BoNT-A:
- Effect: a modest, time-limited tone reduction (about 12 weeks) .
- Safety: systemic adverse events about 1%, highest at GMFCS IV–V and higher doses .
- Phenol gives months-long obturator nerve blocks for adductor tone .
Landmark papers
- McLaughlin et al., Dev Med Child Neurol 2002: meta-analysis of three randomized trials of selective dorsal rhizotomy (90 children). GMFM improved more by +4.0 (P = .008), with benefit rising with the percentage of root tissue cut .
- IDYS (Bonouvrié et al., Ann Neurol 2019): randomized placebo-controlled trial of intrathecal baclofen in dyskinetic cerebral palsy. Goal attainment (GAS T-score) was 38.9 vs 21.0 (P < .001) .
Spasticity in children, mostly from cerebral palsy (CP), is treated on a ladder: therapy and orthoses, oral drugs, focal chemodenervation, then neurosurgery. Each step is matched to the distribution of tone (focal or generalized), its type (pure spasticity or mixed with dystonia), and the child's Gross Motor Function Classification System (GMFCS) level and goals.
- Effective (Novak 2019 evidence review) :
- botulinum toxin, alone or with occupational therapy or casting;
- intrathecal baclofen (ITB);
- selective dorsal rhizotomy (SDR).
- The two neurosurgical options :
- SDR: a permanent tone reduction for the right ambulatory child with pure spastic diplegia.
- ITB: reversible, adjustable, and suited to severe generalized spasticity or dystonia.
Workup for every candidate
- Multidisciplinary assessment: neurosurgery, physiatry or neurology, orthopedics, and physical and occupational therapy.
- Characterize the tone:
- spasticity vs. dystonia or mixed tone, which matters most for SDR;
- distribution: focal, segmental or generalized;
- underlying strength and selective motor control;
- fixed contractures, as opposed to dynamic tone.
- Grade function: GMFCS level, gait analysis where available, and individual, measurable goals, for example gait, sitting, care, comfort or pain.
- Imaging and history: brain and spine MRI (for diagnosis and to exclude a surgical lesion), prematurity, previous orthopedic surgery, hip and spine radiographs.
Botulinum toxin A (BoNT-A)
- Indication: focal or segmental spasticity, for example calf or hamstring tone limiting gait, adductor tone, or upper-limb tone. Often combined with casting or therapy.
- Evidence :
- Trials: 18 RCTs (892 children).
- Spasticity: BoNT-A reduced ankle spasticity (Modified Ashworth Scale mean difference −0.31).
- Duration: the effect fades by about 12 weeks, so injections are repeated.
- Function: early gains are seen when the injections are embedded in rehabilitation.
- Safety :
- Cohort: 1,980 injection episodes in 1,147 children.
- Incontinence: 1%, usually resolving in 1–6 weeks.
- Respiratory admissions: 1.3%.
- Risk factors: higher dose and higher GMFCS level, consistent with systemic spread.
- Practical point: use more conservative dosing at GMFCS IV–V, especially with aspiration or chronic respiratory disease.
Phenol neurolysis
- Indication: chemical neurolysis of a mostly motor nerve when its effect needs to last longer than toxin, or when a toxin dose ceiling is reached.
- Classic target: the anterior branch of the obturator nerve, for adductor spasticity.
- Evidence :
- Series: 22 anterior obturator branches in 11 children, using 5% aqueous phenol guided by landmarks and electrical stimulation.
- Dose: a mean of 0.79 mL per nerve (0.12 mL/kg).
- Result: hip abduction over 45° in all, lasting more than 6 months, with no complications.
- Risks: dysesthesia when mixed sensory nerves are injected, local pain, and systemic toxicity at high doses. Avoid mixed sensory nerves where possible (see caveats).
Intrathecal baclofen (ITB)
- Indication: severe, generalized spasticity and/or dystonia when therapy, oral drugs and focal injections are insufficient or poorly tolerated, typically at GMFCS IV–V. It is reversible and programmable .
- Benefits :
- substantial, sustained tone reduction;
- better comfort, positioning, ease of care and pain;
- variable gains in gross motor function.
- Dyskinetic (dystonic) CP: in the IDYS RCT (GMFCS IV–V, ages 4–24), ITB beat placebo on individual goal attainment (GAS T-score 38.9 vs. 21.0; P < .001), with similar adverse events .
- Screening trial :
- Standard test dose: a 50-μg intrathecal bolus; 25 μg in very small children or in those who rely on tone to walk. Non-responders may get 75–100 μg, at least 24 hours apart.
- Monitoring: cardiorespiratory monitoring for 2 hours.
- Adverse effects: spinal headache, nausea, urinary retention, hypotension, sedation, respiratory depression, seizures.
- Is a trial needed? In one pediatric series:
- Response: tone fell clearly.
- Headache: 21.9% developed a post-dural puncture headache.
- Conversion: 68.8% went on to a pump.
- Authors' view: test dosing was unnecessary in their fragile, mostly GMFCS V population, and the decision should be made case by case.
- Complications are common (142 pumps) :
- Overall: at least one complication in 78%.
- Most frequent: catheter problems and pseudomeningocele, each in 44%.
- Technique lowers risk:
- Pseudomeningocele and CSF leak: less likely with catheter placement via laminotomy rather than needle, and with subfascial tunneling.
- Catheter disconnection and obstruction: less frequent with newer catheters.
- Not risk factors: an existing gastrostomy tube or VP shunt.
- Other risks: infection, overdose and withdrawal, which needs specialist follow-up .
- Withdrawal: pump or catheter failure can cause rebound spasticity, itching, fever and autonomic instability, and can be life-threatening. Families need an emergency plan, and refills must not be missed (see caveats).
Selective dorsal rhizotomy (SDR)
- Principle: section a proportion of the lumbosacral dorsal (sensory) rootlets, chosen with intraoperative EMG stimulation. This reduces afferent drive to the reflex arc and so lowers spasticity permanently.
- Selection criteria vary widely (52 studies) . The most often reported:
- details of the spasticity (94% of studies);
- other movement abnormalities, such as dystonia or ataxia (62%);
- strength (54%);
- diagnosis (50%) and age (44%);
- motivation, follow-up therapy and previous surgery (21–31%).
- Note: most criteria were not based on standardized measurements.
- The usual ideal candidate (common practice; see caveats):
- a child of roughly 3–10 years with pure spastic diplegia, often after preterm birth;
- GMFCS II–III;
- good underlying strength and selective control;
- few fixed contractures;
- a family able to commit to intensive postoperative physical therapy.
- Relative exclusions:
- predominant dystonia, ataxia or athetosis;
- marked weakness, which rhizotomy will unmask;
- fixed contractures or major orthopedic deformity;
- severe scoliosis;
- basal ganglia or cerebellar injury on MRI.
- Efficacy (three RCTs pooled, 90 children) :
- Spasticity: SDR plus physical therapy reduced spasticity (Ashworth −1.2).
- Function: GMFM improved more, by +4.0 (P = .008).
- Dose–response: benefit increased with the percentage of dorsal root tissue cut.
- Long-term outcomes:
- 10 years or more (19 studies, 1,054 patients) :
- Function: GMFCS improved or stayed stable, depending on baseline function.
- Tone: tone reduction was durable.
- Further treatment: few later needed a baclofen pump, but many still needed orthopedic surgery.
- St. Louis adult survey (95 patients, 20–28 years after surgery) :
- Quality of life: 91% said SDR improved it.
- Recommendation: 88% would recommend it.
- Late problems: 38% reported pain, and 57% later had orthopedic surgery.
- Spastic quadriplegia: gait improved in 49% of children operated at 2–5 years vs. 25% at 6–14, and older children more often needed later orthopedic surgery .
SDR complications and spine
- Spinal deformity is frequent on imaging, but mostly follows the natural history of CP:
- McGill (98 children, mean 5.8 years of follow-up) :
- mild scoliosis: 44.8%;
- spondylolisthesis: 19.1%, only in ambulatory children;
- none with clinically significant deficits.
- Toronto (107 children, mean 12.7 years) :
- Scoliosis over 10°, by GMFCS level: 32% at level II, 18% at III, 73% at IV and 92% at V.
- Curves over 40°: none at levels I–III.
- Comparison: rates were consistent with the natural history of CP.
- Ten-year review: spinal deformity was not substantially above natural history .
- Other complications (patchy, rarely limiting):
- Sensory: patchy sensory loss was reported by 8% of adults . Transient dysesthesias are also seen.
- Also seen: bladder dysfunction, CSF leak, wound infection, and unmasked weakness (see caveats).
- Surveillance after SDR: hip and spine radiographs, physical therapy, and orthopedic follow-up through growth .
Choosing among them
- Focal problem: botulinum toxin, with casting or therapy. Use phenol for longer-lasting nerve blocks, such as the obturator nerve.
- Ambulatory child, GMFCS II–III, pure spastic diplegia, good strength: consider SDR, with committed rehabilitation.
- Non-ambulatory child, GMFCS IV–V, generalized spasticity or dystonia, care and comfort goals: ITB. Accept its device burden and complication rate.
- Mixed tone: treat the dystonic component, for example with ITB. SDR helps spasticity, not dystonia.
Related topics
- Spasticity vs. Dystonia: choosing SDR versus ITB or DBS.
- DBS for Dystonia: pallidal stimulation for dystonic CP.
- Matching the Anesthetic to the Operation: Effects on Neuromonitoring: monitoring during rhizotomy.
- Intraoperative Neuromonitoring Under Anesthesia: EMG monitoring during rhizotomy.
- Neurosurgical Delivery of Therapies for Inherited Metabolic and Genetic Brain Disorders: stereotactic, intraventricular and intrathecal delivery of genetic therapies.
- Principles of Pediatric Neuro-Rehabilitation: rehabilitation principles after injury and surgery.
- Degenerative Spinal Disease in Children and Adolescents: back pain, disc herniation and spondylolysis.
- Intrathecal Baclofen Pump Implantation: step-by-step procedure.
- Selective Dorsal Rhizotomy: step-by-step procedure.
- Botulinum Toxin Injection for Spasticity: Common Sites: step-by-step procedure.
References
- Novak I, Morgan C, Fahey M, et al. State of the evidence traffic lights 2019: systematic review of interventions for preventing and treating children with cerebral palsy. Curr Neurol Neurosci Rep 2020;20(2):3. doi:10.1007/s11910-020-1022-z. PMID 32086598. verified
- Tu A, Steinbok P. Long term outcome of selective dorsal rhizotomy for the management of childhood spasticity—functional improvement and complications. Childs Nerv Syst 2020;36(9):1985–1994. doi:10.1007/s00381-020-04747-8. PMID 32577879. verified
- McLaughlin J, Bjornson K, Temkin N, et al. Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. Dev Med Child Neurol 2002;44(1):17–25. doi:10.1017/s0012162201001608. PMID 11811645. verified
- Retkowska-Tomaszewska N, Defort P, Barciszewska AM, et al. Intrathecal baclofen in children with cerebral palsy: a critical review of selection criteria, rehabilitation goals, outcomes, and complications. J Clin Med 2026;15(11):4091. doi:10.3390/jcm15114091. PMID 42278952. verified
- Alghadier M, Alsuwayegh A. Efficacy of botulinum toxin type A for spasticity management and motor function in children with cerebral palsy: a systematic review and meta-analysis of randomized controlled trials. Front Neurol 2026;17:1751493. doi:10.3389/fneur.2026.1751493. PMID 41809197. verified
- Naidu K, Smith K, Sheedy M, et al. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy. Dev Med Child Neurol 2010;52(2):139–144. doi:10.1111/j.1469-8749.2009.03583.x. PMID 20412252. verified
- Kwon JY, Kim JS. Selective blocking of the anterior branch of the obturator nerve in children with cerebral palsy. Am J Phys Med Rehabil 2009;88(1):7–13. doi:10.1097/PHM.0b013e31815b6381. PMID 17993980. verified
- Bonouvrié LA, Becher JG, Vles JSH, et al. The effect of intrathecal baclofen in dyskinetic cerebral palsy: the IDYS trial. Ann Neurol 2019;86(1):79–90. doi:10.1002/ana.25498. PMID 31050023. verified
- Boster AL, Bennett SE, Bilsky GS, et al. Best practices for intrathecal baclofen therapy: screening test. Neuromodulation 2016;19(6):616–622. doi:10.1111/ner.12437. PMID 27434115. verified
- Abdelmageed S, Horak VJ, Mossner J, et al. Safety and efficacy of intrathecal baclofen trials for the treatment of hypertonia: a retrospective cohort study. J Neurosurg Pediatr 2024;33(2):179–184. doi:10.3171/2023.11.PEDS23473. PMID 38064708. verified
- Ryan MV, Freeman LM, Blasco S, et al. Complications of intrathecal baclofen therapy in children and young adults. J Neurosurg Pediatr 2024;34(6):659–670. doi:10.3171/2024.6.PEDS23360. PMID 39303297. verified
- Grunt S, Fieggen AG, Vermeulen RJ, et al. Selection criteria for selective dorsal rhizotomy in children with spastic cerebral palsy: a systematic review of the literature. Dev Med Child Neurol 2014;56(4):302–312. doi:10.1111/dmcn.12277. PMID 24106928. verified
- Park TS, Liu JL, Edwards C, et al. Functional outcomes of childhood selective dorsal rhizotomy 20 to 28 years later. Cureus 2017;9(5):e1256. doi:10.7759/cureus.1256. PMID 28649479. verified
- O'Brien DF, Park TS, Puglisi JA, et al. Effect of selective dorsal rhizotomy on need for orthopedic surgery for spastic quadriplegic cerebral palsy: long-term outcome analysis in relation to age. J Neurosurg 2004;101(1 Suppl):59–63. doi:10.3171/ped.2004.101.2.0059. PMID 16206973. verified
- Golan JD, Hall JA, O'Gorman G, et al. Spinal deformities following selective dorsal rhizotomy. J Neurosurg 2007;106(6 Suppl):441–449. doi:10.3171/ped.2007.106.6.441. PMID 17566400. verified
- Miller SD, Lewis E, Lau J, et al. The effect of selective dorsal rhizotomy on scoliosis in children with cerebral palsy: a long-term follow-up study. J Pediatr Orthop 2025;45(3):158–163. doi:10.1097/BPO.0000000000002878. PMID 39636007. verified
Verification (2026-11-16):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed, and every number against the PubMed abstract.
Caveats:
- The following are standard teaching, not drawn from the cited abstracts:
- the "ideal SDR candidate" profile and relative exclusions (reference 12 shows criteria vary and are rarely standardized);
- ITB withdrawal features;
- phenol risks;
- the SDR complications other than sensory loss and spinal deformity;
- ITB catheter-tip levels in the figure.
- The figure is an original schematic.